The frequency of EGFR And KRAS mutations in the Turkish population with non-small cell lung cancer and their response to erlotinib therapy

1Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012; 62(4): 220-241.SiegelRDeSantisCVirgoKSteinKMariottoASmithTCancer treatment and survivorship statistics, 2012CA Cancer J Clin201262422024110.3322/caac.2114922700443Search in Google Scholar

2Ohashi R, Takahashi F, Cui R, Yoshioka M, Gu T, Sasaki S, et al. Interaction between CD44 and hyaluronate induces chemoresistance in non-small cell lung cancer. Cancer Lett . 2007; 252(2): 225-234.OhashiRTakahashiFCuiRYoshiokaMGuTSasakiSInteraction between CD44 and hyaluronate induces chemoresistance in non-small cell lung cancerCancer Lett2007252222523410.1016/j.canlet.2006.12.02517276588Search in Google Scholar

3Miller VA. EGFR mutations and EGFR tyrosine kinase inhibition in non-small cell lung cancer. Semin Oncol Nurs. 2008; 24(1): 27-33.MillerVAEGFR mutations and EGFR tyrosine kinase inhibition in non-small cell lung cancerSemin Oncol Nurs2008241273310.1016/j.soncn.2007.11.00918222149Search in Google Scholar

4Soria JC, Mok TS, Cappuzzo F, Jänne PA. EGFR-mutated oncogene-addicted non-small cell lung cancer: Current trends and future prospects. Cancer Treat Rev. 2012; 38(5): 416-430.SoriaJCMokTSCappuzzoFJännePAEGFR-mutated oncogene-addicted non-small cell lung cancer: Current trends and future prospectsCancer Treat Rev201238541643010.1016/j.ctrv.2011.10.00322119437Search in Google Scholar

5Cox DA, Der JC. Ras history: Small GTPases. 2010; 1(1): 2-27.CoxDADerJCRas history: Small GTPases20101122710.4161/sgtp.1.1.12178310947621686117Search in Google Scholar

6Adjei A. Blocking oncogenic ras signaling for cancer therapy. J Natl Cancer Inst. 2001; 93(14): 1062-1074.AdjeiABlocking oncogenic ras signaling for cancer therapyJ Natl Cancer Inst200193141062107410.1093/jnci/93.14.106211459867Search in Google Scholar

7Monticone M, Biollo E, Maffei M, Donadini A, Romeo F, Storlazzi CT, et al. Gene expression deregulation by KRAS G12D and G12V in a BRAF V600E context. Mol Cancer. 2008; 7(1): 92-104.MonticoneMBiolloEMaffeiMDonadiniARomeoFStorlazziCTGene expression deregulation by KRAS G12D and G12V in a BRAF V600E contextMol Cancer2008719210410.1186/1476-4598-7-92261504319087308Search in Google Scholar

8Wicki A, Herrmann R, Christofori G. Kras in metastatic colorectal cancer. Swiss Med Wkly. 2010; 140(1): 13112-13119.WickiAHerrmannRChristoforiGKras in metastatic colorectal cancerSwiss Med Wkly20101401131121311910.4414/smw.2010.1311221104470Search in Google Scholar

9Akca H, Demiray A, Yaren A, Bir F, Koseler A, Iwakawa R, et al. Utility of serum DNA and pyrose-quencing for the detection of EGFR mutations in non-small cell lung cancer. Cancer Genet. 2013; 206(6): 73-80.AkcaHDemirayAYarenABirFKoselerAIwakawaRUtility of serum DNA and pyrose-quencing for the detection of EGFR mutations in non-small cell lung cancerCancer Genet20132066738010.1016/j.cancergen.2013.01.00523491080Search in Google Scholar

10Chang ET, Shema SJ, Wakelee HA, Clarke CA, Gomez SL. Uncovering disparities in survival after non-small cell lung cancer among Asian/Pacific Islander ethnic populations in California. Cancer Epidemiol Biomarkers Prev. 2009; 18(8): 2248-2255.ChangETShemaSJWakeleeHAClarkeCAGomezSLUncovering disparities in survival after non-small cell lung cancer among Asian/Pacific Islander ethnic populations in CaliforniaCancer Epidemiol Biomarkers Prev20091882248225510.1158/1055-9965.EPI-09-0332276455019622719Search in Google Scholar

11Arrieta O, Cardona AF, Martín C, López L, Rodríguez L, Bramuglia G. Updated frequency of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC) in Latin America: The Latin-American Consortium for the Investigation of Lung Cancer (CLICaP). J Thorac Oncol. 2015; 10(5): 838-843.ArrietaOCardonaAFMartínCLópezLRodríguezLBramugliaGUpdated frequency of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC) in Latin America: The Latin-American Consortium for the Investigation of Lung Cancer (CLICaP)J Thorac Oncol201510583884310.1097/JTO.000000000000048125634006Search in Google Scholar

12Smits AJJ, Kummer JA, Hinrichs JWJ, Herder GJM, Scheidel-Jacobse KC, Jiwa NM. EGFR and KRAS mutations in lung carcinomas in the Dutch population: increased EGFR mutation frequency in malignant pleural effusion of lung adenocarcinoma. Cell Oncol. 2012; 35(3): 189-196.SmitsAJJKummerJAHinrichsJWJHerderGJMScheidel-JacobseKCJiwaNMEGFR and KRAS mutations in lung carcinomas in the Dutch population: increased EGFR mutation frequency in malignant pleural effusion of lung adenocarcinomaCell Oncol201235318919610.1007/s13402-012-0078-4339634522528563Search in Google Scholar

13Ciećkiewicz S, Olszewski WT, Tysarowski A, Kowalski DM, Głogowski M, Krzakowski M, et al. EGFR mutation testing on cytological and histological samples in non-small cell lung cancer: A Polish, single institution study and systematic review of European incidence. Int J Clin Exp Pathol. 2013; 6(12): 2800-2812.CiećkiewiczSOlszewskiWTTysarowskiAKowalskiDMGłogowskiMKrzakowskiMEGFR mutation testing on cytological and histological samples in non-small cell lung cancer: A Polish, single institution study and systematic review of European incidenceInt J Clin Exp Pathol201361228002812Search in Google Scholar

14Unal OU, Oztop I, Calibasi G, Baskin Y, Koca D, Demir N. Relationship between epidermal growth factor receptor gene mutations and clinicopathological features in patients with non-small cell lung cancer in Western Turkey. Asian Pacific J Cancer Prev. 2013; 14(6): 3705-3709.UnalOUOztopICalibasiGBaskinYKocaDDemirNRelationship between epidermal growth factor receptor gene mutations and clinicopathological features in patients with non-small cell lung cancer in Western TurkeyAsian Pacific J Cancer Prev20131463705370910.7314/APJCP.2013.14.6.370523886169Search in Google Scholar

15Yatabe Y, Kerr KM, Utomo A, Rajadurai P, Tran VK, Du X, et al. EGFR mutation testing practices within the Asia Pacific Region. J Thorac Oncol. 2015; 10(3): 438-445.YatabeYKerrKMUtomoARajaduraiPTranVKDuXEGFR mutation testing practices within the Asia Pacific RegionJ Thorac Oncol201510343844510.1097/JTO.0000000000000422434231725376513Search in Google Scholar

16Melosky B. Review of EGFR TKIs in metastatic NSCLC, including ongoing trials. Front Oncol. 2014; 4: 244.MeloskyBReview of EGFR TKIs in metastatic NSCLC, including ongoing trialsFront Oncol2014424410.3389/fonc.2014.00244416400525309870Search in Google Scholar

17Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005; 97(5): 339-346.ShigematsuHLinLTakahashiTNomuraMSuzukiMWistubaIIClinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancersJ Natl Cancer Inst200597533934610.1093/jnci/dji05515741570Search in Google Scholar

18Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol. 2005; 23(25): 5900-5909.EberhardDAJohnsonBEAmlerLCGoddardADHeldensSLHerbstRSMutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinibJ Clin Oncol200523255900590910.1200/JCO.2005.02.85716043828Search in Google Scholar